Belsomra (Suvorexant) for Elderly Sleep Issues
Belsomra (suvorexant) is appropriate and effective for treating insomnia in elderly patients, with demonstrated improvements in both sleep onset and maintenance over 3 months of nightly use, though it should be started at the lowest dose (10 mg in elderly) due to next-day impairment risks at higher doses. 1, 2
FDA-Approved Indication and Dosing
Belsomra is FDA-approved specifically for insomnia characterized by difficulties with sleep onset and/or sleep maintenance 1. The drug has been studied extensively in elderly populations (≥65 years) with age-adjusted dosing of 15-30 mg, though the FDA-approved maximum dose is 20 mg 1, 2.
Evidence of Efficacy in Elderly Patients
Pooled analyses of Phase III trials in 319 elderly patients demonstrated that suvorexant 30 mg was superior to placebo on both patient-reported and polysomnographic measures of sleep maintenance and onset at Week 1, Month 1, and Month 3 2. The 15 mg dose was also effective across these measures, though onset effects were less evident at later time points 2.
A 2026 meta-analysis of 2,235 patients in the experimental group confirmed that dual orexin receptor antagonists (including suvorexant) reduced wake after sleep onset and latency to persistent sleep while increasing total sleep time after both 1 and 3 months of treatment 3. Importantly, this represents the most recent high-quality evidence specifically addressing elderly populations.
Safety Profile in the Elderly
The safety profile in elderly patients is generally favorable but requires attention to specific risks:
Discontinuation rates due to adverse events were low: 6.4% for 30 mg, 3.5% for 15 mg, versus 5.5% for placebo over 3 months 2. Somnolence was the most common adverse event (8.8% for 30 mg, 5.4% for 15 mg, 3.2% for placebo) 2.
Critical Safety Considerations:
Next-day driving impairment: The 20 mg dose showed clinically meaningful impaired driving performance in some subjects 9 hours after dosing 1. Patients on 20 mg should be cautioned against next-day driving. Lower doses also carry individual variation in sensitivity 1.
Middle-of-night awakening: A single 30 mg dose caused balance impairment (measured by body sway) at 90 minutes after middle-of-night awakening in elderly subjects 1. This is particularly relevant given fall risk in this population.
No significant withdrawal or rebound: Multiple studies showed no clear evidence of withdrawal symptoms or rebound insomnia upon discontinuation after 3 months of nightly use 2, 4, 5.
Real-World Evidence
A 2020 post-marketing surveillance study in Japan evaluated 1,028 patients ≥75 years with multiple comorbidities in daily clinical practice 6. The incidence of adverse drug reactions was 8.17%, with 70-75% of patients showing improvement based on both patient self-assessment and physician assessment 6. This real-world data supports the clinical trial findings in more medically complex elderly populations.
Comparison to Guideline Recommendations
While the available guidelines 7 predate suvorexant's approval (2009 vs. 2014 FDA approval), they establish the framework for elderly insomnia treatment:
Behavioral therapy should be included whenever possible 7. Combination therapy (behavioral + pharmacologic) was more efficacious than either alone in the single RCT conducted in older adults 7.
Start at the lowest available dose for any hypnotic in elderly patients 7.
Benzodiazepine receptor agonists have lower frequency and severity of adverse effects than older benzodiazepines 7. Suvorexant, as an orexin receptor antagonist, represents a mechanistically different approach with no demonstrated potential for abuse or significant motor/cognitive impairment at therapeutic doses 7.
Practical Dosing Algorithm for Elderly Patients:
- Start with 10 mg (the lowest available dose for elderly)
- Assess response after 1-2 weeks
- If inadequate response and no adverse effects, may increase to 15 mg, then 20 mg maximum
- Avoid 20 mg dose in patients who must drive the next morning or operate heavy machinery
- Counsel all patients about potential next-day impairment regardless of dose due to individual variation
- Warn about middle-of-night awakening risks (balance impairment, fall risk)
Special Population: Alzheimer's Disease
A 4-week RCT in 285 patients with mild to moderate Alzheimer's disease (ages 50-90) showed statistically significant improvements in both total sleep time and wake after sleep onset with suvorexant 10-20 mg compared to placebo 1. This extends the evidence base to cognitively impaired elderly patients.
Common Pitfalls to Avoid:
- Don't use the 20 mg dose as first-line in elderly despite it being studied in trials; start with 10 mg
- Don't dismiss next-day impairment concerns even at lower doses—individual sensitivity varies
- Don't forget to assess middle-of-night bathroom trips as a fall risk scenario
- Don't use as monotherapy without considering behavioral interventions, which provide longer-term sustained benefit 7